Please login to the form below
Ovarian canncer
This page shows the latest Ovarian canncer news and features for those working in and with pharma, biotech and healthcare.
Another NICE no for AZ’s new ovarian cancer drug
Cost watchdog wants more information for Lynparza. . NICE is once again saying no to AstraZeneca's new ovarian cancer drug - but is opening up a second consultation on its decision. ... The Institute is minded, in preliminary draft guidance, to reject
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA approves Seagen/Genmab’s antibody-drug conjugate Tivdak for women with advanced cervical cancer
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Gilead’s Veklury (remdesivir) cuts risk of severe COVID-19 by 87%
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- WHO to test three more potential COVID-19 treatments
- EU “still interested” in Valneva COVID vaccine despite UK snub
- FDA green lights study of phage-based drug for resistant infections
- First oral antiviral drug for COVID-19 reviewed by Health Canada
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
